Catherex, Amgen deal

Amgen is acquiring Catherex for $10.5 million up front. Catherex shareholders are also eligible for regulatory and sales milestones related to Amgen’s Imlygic talimogene laherparepvec, plus royalties until the end of 2020. The oncolytic virus is approved in the U.S. and EU to treat advanced metastatic melanoma. ...